林贝他因促进支气管肺功能失调症中的血管生成
Wangdui Cili1, Zhiye Qi1, Qinghua Zhong1
1Department of Pediatrics, The First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan Province 650032, China.
Toxicology and applied pharmacology
|March 15, 2025
概括
普罗林贝他因是一种天然化合物,促进血管生长,并减少支气管肺功能失调 (BPD) 模型中的肺损伤. 这表明它有可能成为婴儿BPD的新治疗方法.
科学领域:
- 新生儿医学 新生儿医学
- 药理学 药理学是指药理学的学科.
- 肺部生物学 肺部生物学
背景情况:
- 支气管肺功能障碍症 (BPD) 是早产婴儿常见和严重的肺部疾病.
- 它的特点是肺部发育异常和显著的发病率.
- 目前对BPD的治疗方法有限,这凸显了对新型治疗策略的需求.
研究的目的:
- 在临床前的BPD模型中研究proline betaine的治疗潜力.
- 探索proline betaine可能对肺部发育和损伤产生影响的机制.
主要方法:
- 网络药理学被用来识别与BPD相关的普罗林贝他因的潜在点.
- 在体外研究中评估了普罗林贝他因对人类静脉内皮细胞 (HUVEC) 的影响,以评估增殖和血管生成.
- 一种体内高氧诱导的BPD大鼠模型被用于评估肺损伤,血管新生和纤维化.
主要成果:
- 林贝他因在体外对HUVECs表现出显著的益血管效应,以剂量依赖的方式增强管道形成和毛细血管长度.
- 在BPD小鼠模型中,通过增加膜化和减少原体沉积,林贝他因治疗改善了肺部结构.
- 从机理上讲,林贝他因上调了VEGF和VEGFR2的表达,并激活了MEK/ERK通路,这对其治疗效果至关重要.
结论:
- 在BPD模型中,proline betaine有效地增强血管生成并减轻肺损伤.
- 治疗效益通过MEK/ERK信号通路进行介导.
- 林贝他因作为一种新型治疗药物,有望在新生儿中治疗支气管肺功能障碍.
相关概念视频
01:24Regulation of Angiogenesis and Blood Supply
2.5K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.5K
01:10Mechanism of Angiogenesis
5.2K
Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
5.2K
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
141
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
141